Drug intelligence / Profile preview

NI-0701

Development stage: Phase 1
Lead developer: Lightchain Bioscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NI-0701 is a fully human monoclonal antibody developed for the treatment of autoimmune and inflammatory diseases, including asthma. It acts as an inhibitor of the chemokine CCL5 (also known as RANTES), thereby blocking its interaction with receptors and reducing inflammation mediated by this pathway. The drug was originally developed by NovImmune and later by Light Chain Bioscience. Its primary mechanism is antagonism of CCL5, which plays a key role in recruiting immune cells to sites of inflammation. Clinical development has included phase I studies in healthy volunteers using intravenous infusion[1][2][4][5].

Other names: Alpha-RANTES

Targets

CCL5 (C-C Motif Chemokine Ligand 5)

Beyond the preview

Go deeper on NI-0701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NI-0701.

Explore the full profile